<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="2" ids="39026">Low density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) receptor-mediated uptake and cytotoxic effects of N4-<z:chebi fb="0" ids="26755">octadecyl</z:chebi>-1-beta-D-arabinofuranosylcytosine (NOAC) were studied in Daudi <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>NOAC was either incorporated into <z:chebi fb="15" ids="39026">LDL</z:chebi> or liposomes to compare specific and unspecific uptake mechanisms </plain></SENT>
<SENT sid="2" pm="."><plain>Binding of <z:chebi fb="15" ids="39026">LDL</z:chebi> to Daudi cells was not altered after NOAC incorporation (K(D) 60 nM) </plain></SENT>
<SENT sid="3" pm="."><plain>Binding of liposomal NOAC was not saturable with increasing concentrations </plain></SENT>
<SENT sid="4" pm="."><plain>Specific binding of NOAC-<z:chebi fb="15" ids="39026">LDL</z:chebi> to Daudi cells was five times higher than to human lymphocytes </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi> receptor binding could be blocked and up- or down-regulated </plain></SENT>
<SENT sid="6" pm="."><plain>Co-incubation with <z:chebi fb="0" ids="23359">colchicine</z:chebi> reduced NOAC-<z:chebi fb="15" ids="39026">LDL</z:chebi> uptake by 36% </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggested that NOAC-<z:chebi fb="15" ids="39026">LDL</z:chebi> is taken up via the <z:chebi fb="15" ids="39026">LDL</z:chebi> receptor pathway </plain></SENT>
<SENT sid="8" pm="."><plain>In an in vitro cytotoxicity test, the IC50 of NOAC-<z:chebi fb="15" ids="39026">LDL</z:chebi> was about 160 microM, whereas with liposomal NOAC the IC50 was 40 microM </plain></SENT>
<SENT sid="9" pm="."><plain>Blocking the <z:chebi fb="15" ids="39026">LDL</z:chebi> receptors with empty <z:chebi fb="15" ids="39026">LDL</z:chebi> protected 50% of the cells from NOAC cytotoxicity </plain></SENT>
<SENT sid="10" pm="."><plain>The cellular distribution of NOAC-<z:chebi fb="15" ids="39026">LDL</z:chebi> or NOAC-liposomes differed only in the membrane and nuclei fraction with 13% and 6% respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Although it is more convenient to prepare NOAC-liposomes as compared to the loading of <z:chebi fb="15" ids="39026">LDL</z:chebi> particles with the drug, the receptor-mediated uptake of NOAC-<z:chebi fb="15" ids="39026">LDL</z:chebi> provides an interesting rationale for the specific delivery of the drug to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> that express elevated numbers of <z:chebi fb="15" ids="39026">LDL</z:chebi> receptors </plain></SENT>
</text></document>